Association of polymorphisms of A260G and A386G in DAZL gene with male infertility: a meta-analysis and systemic review

Ping Chen, Xiao Wang, Chang Xu, He Xiao, Wen-Hao Zhang, Xing-Huan Wang, Xin-Hua Zhang

To investigate the association of single nucleotide polymorphism 260 and 386 (SNP260 and SNP386) gene with male infertility, an electronic search was performed to identify case-control studies evaluating the relationship of SNP260 or SNP386 of deleted in azoospermia-like (DAZL) and male infertility. Review Manager 5 was used to process the meta-analysis and other statistical analysis. A total of 139 records were retrieved, of which 13 case-control studies with total 2715 patients and 1835 normozoospermic men were included. SNP260 was found not to play a functional role in male oligo/azoospermia either for Caucasians or for Asians. But for SNP386, models of allele (A/G), co-dominant (AA/AG + GG), super-dominant (AA + GG/AG) and self-dominant (AA/AG) had a strong correlation to spermatogenic failure with related odds ratio being 0.15 (95% confidence interval [95% CI] 0.07 to 0.34, \( P < 0.00001 \)), 0.16 (95% CI 0.17 to 0.35, \( P < 0.00001 \)), 0.15 (95% CI 0.16 to 0.33, \( P < 0.00001 \)) and 0.15 (95% CI 0.16 to 0.33, \( P < 0.00001 \)), respectively. Moreover, this correlation was only found in the Chinese Han population (decreasing around 85% risk of oligo/azoospermia infertility) and not found in India, Japan, and Caucasian countries. Our analysis demonstrated that SNP260 of DAZL did not contribute to oligo/azoospermia while SNP386 was correlated to male infertility. However, this correlation was only found in China with a country-specific and ethnicity-specific manner.

Asian Journal of Andrology (2016) 18, 96–101; doi: 10.4103/1008-682X.153542; published online: 18 May 2015

Keywords: deleted in azoospermia-like; male infertility; meta-analysis; polymorphism; single nucleotide polymorphisms

INTRODUCTION

The prevalence of infertility may be as high as 15% with about 50% of cases attributed to male factors. Male infertility is commonly believed to result from an exogenous insult after birth or in utero, such as an exposure to gonadotoxins, trauma, or infection, but there is no effective treatment for patients with nonobstructive azoospermia, in which there is an absence of mature sperm in the testes. This suggests the exogenous insult after birth or in utero may not play a role for nonobstructive azoospermia patients. But from an evidence-based medicine perspective, rigorous studies demonstrating direct cause and effect relationship in human infertility are frequently lacking. Changes in sperm motility parameters are the predominant factor in most cases of male infertility, however, in 30%–45%, the cause of the abnormal sperm parameters is not identified (idiopathic male infertility). In recent years, there has been remarkable progress in understanding the regulation of spermatogenesis and the clinical impact of male infertility, largely as a result of the molecular and biochemical insights. It is estimated that in about 30% of cases, male infertility is due to a genetic disorder such as aneuploidy, structural chromosomal abnormalities, DNA damage, and gene mutations including a variety of newly discovered genes. The most frequent causes are rare variants causing the spermatogenic dysfunction.

The incidence of chromosomal abnormalities is 5.8% for infertile men. Of these, sex chromosome abnormalities account for 4.2% and autosomal abnormalities for 1.5%. Among the azoospermia/severe oligozoospermia patients, microdeletions of the Y chromosome, including deleted in azoospermia (DAZ) gene family, are the major, well-characterized genetic causes. DAZ-like (DAZL), an autosomal homolog of DAZ, localized on chromosome 3 and expressed in germ cells, is essential for germ cell lineage development in several species. Mutation analysis of DAZL in infertile men identified the first two nonsynonymous single nucleotide polymorphism (SNP) at nucleotide position 260 (exon 2) and 386 (exon 3), resulting in the amino acid exchange T12A and T54A, respectively. In recent years, a number of studies investigated the possible association of azoospermia or oligozoospermia with A260G or A386G sites polymorphism but controversies exist. Tüttelmann et al. summarized all polymorphisms and male infertility that have been investigated in single case-control studies in their meta-analysis in 2007 and revealed significant associations between polymorphism and spermatogenic failure only for AZF gr/gr deletions and MTHFR 677C → T but not for POLG, DAZL, USP26, or FSHR. However, for DAZL polymorphism, just A260G gene loci were analyzed with only six included studies in their review. Thus, no complete meta-analysis has been conducted to verify this correlation. In this review, we apply the methods of evidence-based medicine to evaluate and analyze the documented studies of DAZL polymorphism and male infertility so as to provide a more systematic and comprehensive assessment of their associations.
MATERIALS AND METHODS

Inclusion criteria
Case-control studies investigated the association of SNP260 or SNP386 of DAZL with male infertility should provide sufficient data that could be extracted and used to calculate odds ratios (ORs) and 95% confidence intervals (95% CI). Patients were diagnosed as male infertility with sperm count <20 × 10^6 ml⁻¹ or no sperm in at least two seminal fluid examinations after 3/4 days of sexual abstinence, which was accordant with 2012 European Association of Urology⁴ or 2010 WHO Laboratory Manual for the Examination and Processing of Human Semen.¹⁰ There was no limitation to the methods of assays for detecting SNP of DAZL.

Exclusion criteria
Repeat publications and grey literature that were unpublished and reported superficially studies, such as in the form of an abstract and the studies in which sample size <10 or main data could not be obtained would be excluded.

Literature search strategy
We performed an electronic search of PubMed (1966 to September 2013), ScienceDirect Online (1995 to September 2013), Wiley Online Library (2010 to September 2013), China National Knowledge Infrastructure (CNKI) (1999 to September 2013), VIP Database (2000 to September 2013) and Chinese Dissertation Database (CDDB) (1998 to September 2013) for case-control studies evaluating the relationship of SNP260 or SNP386 of DAZL and male idiopathic oligozoospermia (sperm number <20 × 10⁶ spermatozoa per ml) or azoospermia. The search keywords were used with different combinations with both medical subject headings terms and text words: “male infertility” or “male sterility” or “male infertility” or “male sterile” or “male dysgenensis” or “azoospermia” or “oligozoospermia” or “azoospermic” or “oligozoospermic” or “OAT” plus “DAZL” or “deleted in azoospermia-like” or “spgyla” or “Daz-like autosomal” or “SNP260” or “SNP386” or “T12A” or “T54A” or “SNP.” Publication date was not restricted in our search. Reference lists of the included studies and supplemental materials were checked manually to further identify related studies. Meanwhile, published genome-wide association studies (GWASs) about male infertility were also examined.

Selection of studies
Two reviewers (CX and HX) independently screened the title, abstract, and keywords of each article retrieved. Full-text papers were screened for further assessment if the information given suggested that the study fulfilled the inclusion criteria and did not meet the exclusion criteria. Discrepancies were settled by discussion and consensus with all the authors.

Data extraction
The following information was independently extracted from the identified studies by three reviewers (CX, HX and WHZ) using a standard form with first author’s surname, year of publication, country, ethnicity, allele frequencies, and genotype distribution in cases and controls, method of genotype test and Hardy–Weinberg equilibrium (HWE) test. Ethnicities were stratified as Asians, Caucasians, and others. The authors of original studies were consulted for missing information where necessary. Discrepancies were resolved by open discussion.

HWE test
HWE test was performed, and the HWE significance of the control groups was calculated with StataSE 12.0 (StataCorp LP, College Station, TX, USA) when the original information was not provided.

Data synthesis and analysis
The significance for five genetic models (allele, dominant, recessive, co-dominant, and super-dominant genetic models) was evaluated for each study separately. All the associations were indicated as ORs with the corresponding 95% CI. Based on the individual ORs, a pooled OR was estimated. Subgroup analysis was also performed by stratifying country and ethnicity. Fixed-effects model¹¹ or the random-effects model¹² of meta-analysis was chosen according to the results of heterogeneity tests among individual studies by Review Manager 5 (The Cochrane Library). The significance of the pooled OR was determined using the Z test and P < 0.05 was considered statistically significant.

Heterogeneity assumption was assessed by Cochran’s Q statistic¹³ and F statistic. The heterogeneity was considered statistically significant if P < 0.10. The random-effects model (if P < 0.10 and I² >50%) or the fixed-effects model (if P ≥ 0.10 and I² <50%) was used to pool the ORs. Egger’s test was used to evaluate the publication bias, which was considered when P < 0.05.

RESULTS

Characteristics of included studies
Using the database search strategy, a total of 139 records were retrieved from PubMed, Science Direct, Wiley Online Library, CNKI, VIP and CDBD, of which 13 case-control studies finally met full inclusion criteria for this review.¹⁴⁻²⁵ No dataset of genotype frequencies of SNP was acquired from GWASs of male infertility.²⁶⁻²⁷ Supplementary Figure 1 depicts the flowchart of the search process. Supplementary Table 1 describes the characteristics of the included trials. Supplementary Tables 2 and 3 describe the distribution of genotypes and allele frequencies of SNP260 and SNP386 in infertile men and control group, respectively.

Meta-analysis of single nucleotide polymorphism 260
A total of ten studies were included for the analysis of SNP260. Figure 1 showed the meta-analysis for allele model (A/G), dominant model (AA/AG + GG), recessive model (AA + AG/GG), co-dominant model (AA/AG), co-dominant model (AA + GG/GG) and super-dominant model (AA + GG/AG), respectively. F standing for the heterogeneity among studies for all models was 0%; thus, fixed-effects models were applied. Related ORs of the six models were 0.88 (95% CI 0.73 to 1.07, P = 0.21), 0.85 (95% CI 0.69 to 1.05, P = 0.12), 0.70 (95% CI 0.31 to 1.58, P = 0.39), 0.83 (95% CI 0.67 to 1.02, P = 0.08), 1.39 (95% CI 0.61 to 3.17, P = 0.43) and 0.82 (95% CI 0.66 to 1.02, P = 0.08), respectively, which indicated that SNP260 was not significantly associated with male infertility for all models. Sensitivity analysis was performed by eliminating each of the included studies, and the statistical significance was not changed, suggesting that the results above were reliable. Egger’s test revealed that there was no any obvious evidence of publication bias (P = 0.737).

Table 1 shows the summary of the subgroup analysis stratified by different ethnicity. No significant difference was detected between each subgroup, either.

Meta-analysis of single nucleotide polymorphism 386
Single nucleotide polymorphism 386 of DAZL was not found in populations from Germany, Italy, Japan, Northern China, and Western India. It was only detected in populations from Western China, Taiwan of China, Northern, and Eastern India. Figure 2 showed the meta-analysis for the allele model (A/G), dominant model (AA/AG + GG), recessive model (AA + AG/GG), co-dominant model (AA/AG), co-dominant model (AA + GG/GG), and super-dominant model (AA + GG/AG), in...
which \( P \) standing for the heterogeneity among the studies was 19%, 28%, 0%, 38%, 0%, and 38%, respectively. Thus fixed-effects models were applied. Related OR was 0.15 (95% CI 0.07 to 0.34, \( P < 0.00001 \)), 0.16 (95% CI 0.07 to 0.35, \( P < 0.00001 \)), 2.11 (95% CI 0.24 to 18.67, \( P = 0.50 \)), 0.15 (95% CI 0.06 to 0.33, \( P < 0.00001 \)), 0.45 (95% CI 0.05 to 4.04, \( P = 0.48 \)) and 0.15 (95% CI 0.06 to 0.33, \( P < 0.00001 \)), indicating that model of A/G, AA + + GG, AA + + AG AA/AG of SNP386 was significantly associated with spermatogenic failure, while for model AA + + GG and AA/AG, the difference was not significant. Sensitivity analysis was performed by eliminating each of the included studies, and the statistical significance was not changed, suggesting that the results above were reliable. Egger's test revealed that there was obvious evidence of publication bias (\( P = 0.009 \)).

**Table 1** shows subgroup analysis stratified by different countries. For allele model (A/G), dominant model (AA/AG + GG), super-dominant model (AA + GG/AG) and co-dominant model (AA/AG) model, we detected significant association of SNP386 with male infertility. But the significant difference was kept consistent only in China. In co-dominant model (AA/AG) and recessive model (AA + AG/GG), the genotype of GG was not detected in India and meta-analysis of this subgroup was not applicable.

**DISCUSSION**

This meta-analysis and systemic review investigated the association of DAZL polymorphisms and male infertility. Our novel data demonstrated that SNP260 of DAZL did not contribute to oligozoospermia or azoospermia, while SNP386 of DAZL was correlated to male infertility only in the Chinese Han.

Polymorphisms or genetic variants in genes involved in spermatogenesis are considered potential risk factors which may contribute to the severity of spermatogenic failure. Several polymorphic variants have been described in association with oligo/
The association of SNP260 and SNP386 with male infertility
P Chen et al

Azoospermia, among which two DAZL polymorphisms (SNP260 and SNP386) were the first description of SNPs of autosomal genes influencing human spermatogenesis. Analysis of the distribution and frequency of these SNPs among fertile and infertile men has demonstrated a strong association of the heterozygous genotype for SNP386 with spermatogenic failure for Asians while it was not detected in Caucasians. But no such association could be found for SNP260.

In order to provide a complete assessment, we performed the present meta-analysis of 13 independent case-control studies with total number of 2715 patients and 1835 normozoospermic men, of which there were 2500 oligo/azoospermic men. We found that SNP260 of DAZL had no correlation with male oligozoospermia or azoospermia which was consistent with Tüttelmann's meta-analysis including 6 studies with 1600 patients and 1100 controls of different ethnic origin. In this previous review, the authors did not perform meta-analysis on the relationship between SNP386 and male infertility. Instead, they did a literature review and drew a conclusion that SNP386 was never found in non-Chinese populations. However, SNP386 was later detected in India though there was no association with male infertility.

We further conducted a subgroup analysis by ethnicity and country in the current meta-analysis. In the stratified analysis according to ethnicity, we found that SNP260 had no correlation with male oligozoospermia or azoospermia either in Caucasian or Asian populations. For SNP386, it was only detected in Asians and not in Caucasians. We also further performed the stratified analysis by country and demonstrated that models of SNP386 of allele (A/G), dominant (AA/AG + GG), co-dominant (AA/AG), and super-dominant (AA + GG/AG) had a strong association with spermatogenic failure in China. Although these variants were detected in northern and eastern India, the difference did not reach statistical significance. Therefore, functional DAZL A/G polymorphism may play a penetrance role in male oligo/azoospermia susceptibility in ethnicity-specific and country-specific manners.

Discrepancies between results of association studies are a rather frequent phenomenon and may be related to many different factors.

Table 1: Subgroup analysis stratified by different population and countries

| Gene site | Genetic model | Population | P Q test | I² (%) | P Z test | OR (95% CI) |
|-----------|---------------|------------|----------|--------|----------|-------------|
| SNP260    | Allele (A/G)  | Overall    | 0.79     | 0      | 0.21     | 0.88 (0.73–1.07) |
|           |               | Caucasian  | 0.77     | 0      | 0.24     | 0.83 (0.62–1.13) |
|           |               | Asian      | 0.65     | 0      | 0.52     | 0.92 (0.71–1.19) |
|           | Dominant (AA/AG+GG) | Overall    | 0.8      | 0      | 0.12     | 0.85 (0.69–1.05) |
|           |               | Caucasian  | 0.57     | 0      | 0.18     | 0.80 (0.57–1.11) |
|           |               | Asian      | 0.69     | 0      | 0.37     | 0.88 (0.67–1.16) |
|           | Recessive (GG/AA+AG) | Overall    | 0.67     | 0      | 0.86     | 1.43 (0.63–3.25) |
|           |               | Caucasian  | 0.64     | 0      | 0.28     | 1.22 (0.31–4.87) |
|           |               | Asian      | 0.48     | 0      | 0.88     | 1.57 (0.58–4.29) |
|           | Co-dominant (AA/AG) | Overall    | 0.72     | 0      | 0.08     | 0.83 (0.67–1.02) |
|           |               | Caucasian  | 0.44     | 0      | 0.16     | 0.78 (0.56–1.10) |
|           |               | Asian      | 0.6      | 0      | 0.27     | 0.85 (0.65–1.13) |
|           | Co-dominant (AA/GG) | Overall    | 0.66     | 0      | 0.43     | 1.39 (0.60–3.17) |
|           |               | Caucasian  | 0.46     | 0      | 0.87     | 1.12 (0.28–4.52) |
|           |               | Asian      | 0.47     | 0      | 0.38     | 1.57 (0.58–4.30) |
|           | Super-dominant (AA+GG/AG) | Overall    | 0.72     | 0      | 0.08     | 0.82 (0.66–1.02) |
|           |               | Caucasian  | 0.41     | 0      | 0.15     | 0.78 (0.56–1.09) |
|           |               | Asian      | 0.61     | 0      | 0.26     | 0.85 (0.65–1.13) |
| SNP386    | Allele (A/G)  | Overall    | 0.29     | 19     | <0.01    | 0.15 (0.07–0.34) |
|           |               | India      | 0.4      | 0      | 0.79     | 0.80 (0.16–4.09) |
|           |               | China      | 0.79     | 0      | <0.01    | 0.11 (0.04–0.28) |
|           | Dominant (AA/AG+GG) | Overall    | 0.23     | 28     | <0.01    | 0.16 (0.07–0.35) |
|           |               | India      | 0.4      | 0      | 0.79     | 0.80 (0.16–4.09) |
|           |               | China      | 0.53     | 0      | <0.01    | 0.11 (0.04–0.28) |
|           | Recessive (GG/AA+AG) | Overall    | 0.89     | 0      | 0.5      | 2.11 (0.24–18.67) |
|           |               | India      | 0.89     | 0      | 0.5      | 2.11 (0.24–18.67) |
|           |               | China      | 0.88     | 0      | 0.48     | 0.45 (0.05–4.04) |
|           | Co-dominant (AA/AG) | Overall    | 0.19     | 38     | <0.01    | 0.15 (0.06–0.33) |
|           |               | India      | 0.4      | 0      | 0.79     | 0.80 (0.16–4.09) |
|           |               | China      | 0.88     | 0      | <0.01    | 0.09 (0.03–0.26) |
|           | Co-dominant (AA/GG) | Overall    | 0.86     | 0      | 0.48     | 0.45 (0.05–4.04) |
|           |               | India      | 0.86     | 0      | 0.48     | 0.45 (0.05–4.04) |
|           |               | China      | 0.89     | 0      | <0.01    | 0.09 (0.03–0.26) |

OR: odds ratio; CI: confidence interval; SNP: single nucleotide polymorphisms
An important feature of these studies is that the discrepancy between Caucasian analysis and the Chinese studies is not related to sampling biases (small sample size, inadequate control group or population substructuring), but it is related to the complete absence of the “at risk” SNP in Caucasians, indicating that in Western countries, this polymorphism is probably absent or rare. This remarkable difference is paradigmatic as it shows how ethnic background is important for polymorphisms involved in spermatogenesis, thereby underscoring that different genetic risk factors may be present in different populations. A similar phenomenon is observed for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations causing the azoospermia because of congenital bilateral absence of vas deferens. The frequency of a particular CFTR mutation is also influenced by the ethnic composition of the population analyzed. Our study, therefore, contributes to a better definition of clinically relevant tests, specifically based on the ethnic origin of the infertile patients.

The low heterogeneity in our analysis contributes to highly reliable results through meta-analysis. There is no publication bias in the studies about DAZL SNP260. But there exists publication bias about SNP386 of DAZL. The sources of bias might be from the small sample sizes or incorporated literatures of low quality. Bias may be also resulted from more chance of positive findings published than the negative ones.

The results of our meta-analysis should be interpreted after taking into consideration several inevitable study limitations. First, although we set a comprehensive search strategy for the retrieval of eligible studies, we cannot eliminate that some studies might have been lost. Second, there is language limitation as current meta-analysis only contains English and Chinese literature with some articles possibly published in other languages and not accessible to the international journals. Finally, our results are based on unadjusted ORs while a

Figure 2: The association of single nucleotide polymorphism 386 with male infertility. A forest plot in (a) allele model (A/G), (b) dominant model (AA/AG + GG), (c) recessive model (AA + AG/GG), (d) co-dominant model (AA/AG), (e) co-dominant model (AA/GG), (f) super-dominant model (AA + GG/AG). The association was indicated as odds ratio (OR) with the corresponding 95% confidence interval (CI). The OR estimate of each study is marked with a solid black square. The size of the square represents the weight that the corresponding study exerts in the meta-analysis. The CIs of pooled estimates are displayed as a horizontal line through the diamond. OR < 1 indicates increased risk of male infertility. A: wild type gene and G: mutant gene.
more precise estimation should take into account the effect of multiple confounders such as age and disease severity on the association. Therefore, multicenter, large sample sizes, high-quality case-control or cohort trials are further required to study the exact relationship between DAZL polymorphisms and male oligozoospermia or azoospermia.

CONCLUSIONS
Our analysis demonstrated that SNP260 of DAZL did not contribute to oligozoospermia or azoospermia in any ethnic subgroups. Instead, SNP386 was correlated to male infertility though this correlation was only found in China with a country-specific and ethnicity-specific manner. However, high-quality trials are further required to study the exact relationship between DAZL polymorphisms and male infertility.

AUTHOR CONTRIBUTIONS
All authors have fulfilled all conditions required for authorship. XHZ performed the electronic search, selected studies, extracted data and performed quality assessment. PC and XW analyzed data and conducted a meta-analysis. XHZ and XHW supervised the research, edited and drafted revisions to the article.

COMPETING INTERESTS
The authors declare no competing interests.

ACKNOWLEDGMENTS
XHZ is supported by the National Natural Science Foundation of China (No. 81270843 and No. 81160086).

Supplementary information is linked to the online version of the paper on the Asian Journal of Andrology website.

REFERENCES
1 Miyamoto T, Tsujimura A, Miyagawa Y, Koh E, Namiki M, et al. Male infertility and its causes in humans. Adv Urol 2012; 2012; 384520.
2 Pierik FH, Van Ginneken AM, Dohle GR, Vreeburg JT, Weber RF. The advantages of standardized evaluation of male infertility. Int J Androl 2000; 23: 340–60.
3 Vogt PH. Molecular genetics of human male infertility: from genes to new therapeutic perspectives. Curr Pharm Des 2004; 10: 471–500.
4 Johnson MD. Genetic risks of intracytoplasmic sperm injection in the treatment of male infertility: recommendations for genetic counseling and screening. Fertil Steril 1998; 70: 397–411.
5 Xu PY, Moore FL, Pera RA. A gene family required for human germ cell development evolved from an ancient meiotic gene conserved in metazoans. Proc Natl Acad Sci U S A 2001; 98: 7414–9.
6 Xu EH, Lee DF, Klies A, Turek PJ, Kornberg TB, et al. Human BOULE gene rescues meiotic defects in infertile flies. Hum Mol Genet 2003; 12: 169–75.
7 Teng YN, Lin YM, Lin YH, Tsao SY, Hsu CC, et al. Association of a single-nucleotide polymorphism of the deleted-in-azooospermia-like gene with spermatogenic failure. J Clin Endocrinol Metab 2002; 87: 5258–64.
8 Töttmann F, Rijpstra-De Meets Y, Nieschlag E, Simonis M. Gene polymorphisms and male infertility – a meta-analysis and literature review. Reprod Biomed Online 2007; 15: 653–68.
9 Jungwirth A, Giwercman A, Tournaye H, Diemer T, Kopa Z, et al. European Association of Urology guidelines on Male Infertility: the 2012 update. Eur Urol 2012; 62: 324–32.
10 Lu JC, Huang YF, Lü NQ. WHO laboratory manual for the examination and processing of human semen: its applicability to andrology laboratories in China. Zhonghua Nan Ke Xue 2010; 16: 867–71.
11 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–48.
12 DeSimone R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28: 105–14.
13 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–58.
14 Teng YN, Lin YM, Sun HF, Hsu PY, Chung CL, et al. Association of DAZL haplotypes with spermatogenic failure in infertile men. Fertil Steril 2006; 86: 129–35.
15 Bartoloni L, Cazzadoro C, Ferlin A, Garolla A, Foresta C. Lack of the T54A polymorphism of the DAZL gene in infertile Italian patients. Mol Hum Reprod 2004; 10: 613–5.
16 Tschanter P, Kostova E, Luetjens CM, Cooper TG, Nieschlag E, et al. Association of the A260G and A386G DAZL single nucleotide polymorphisms with male infertility in a Caucasian population. Hum Reprod 2004; 19: 2771–6.
17 Yang XJ, Shinka T, Nozawa S, Yan HT, Yoshiike M, et al. Survey of the two polymorphisms in DAZL, an autosomal candidate for the azoospermic factor, in Japanese infertile men and implications for male infertility. Mol Hum Reprod 2005; 11: 513–5.
18 Thangari, K, Deepa SR, Pavan K, Gupta NA, Reddy P, et al. A to G transitions at 260, 386 and 437 in DAZL gene are not associated with spermatogenic failure in Indian population. Int J Androl 2006; 29: 510–14.
19 Wen XH, Zhang JY, Zuo WJ, Wu W. Autosomal DAZL single nucleotide polymorphisms not associated with male infertility in northeast China. Zhonghua Nan Ke Xue 2007; 13: 713–7.
20 Poongothai J, Gopenath TS, Manonayaki S. A386G transition in DAZL gene is not associated with spermatogenic failure in Tamil Nadu, South India. Indian J Hum Genet 2008; 14: 16–9.
21 Singh K, Raman R. A386G polymorphism of the DAZL gene is not associated with idiopathic male infertility in North India. J Hum Reprod Sci 2009; 2: 54–6.
22 Chen P, Ma M, Li Z, Zhang S, Xu D, et al. Phenotypic expression of partial A2F deletions is independent of the variations in DAZL and BOULE in a Han population. J Androl 2010; 31: 163–8.
23 Kumar K, Venkatesh S, Sharma PR, Tiwari PK, Dada R. DAZL 260A>G and MTHFR 677C>T variants in sperm DNA of infertile Indian men. Indian J Biochem Biophys 2011; 48: 422–6.
24 Becherini L, Guarducci E, Degli’Innocenti S, Rotondi M, Forti G, et al. DAZL polymorphisms and susceptibility to spermatogenic failure: an example of remarkable ethnic differences. Int J Androl 2004; 27: 375–81.
25 Wang H, Ding XP, Zha YJ, Zhang M. Research on the relationship between the SNPs of DAZL and male infertility by multi-analyze suspension array. J Sichuan Univ 2009; 6: 1135–8.
26 Aton KE, Carrell DT. Genome-wide study of single-nucleotide polymorphisms associated with azoospermia and severe oligozoospermia. J Androl 2009; 30: 711–25.
27 Aton KE, Krausza, Carrell DT. Evaluation of 172 candidate polymorphisms for association with oligozoospermia or azoospermia in a large cohort of men of European descent. Hum Reprod 2010; 25: 1383–97.
28 Dowsett AT, Yong EL, Clark M, McLachlan R, de Krester DM, et al. Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene. Lancet 1999; 354: 640–3.
29 Ruiz-Pesini E, Lapeña AC, Díez-Sánchez C, Pérez-Martos A, Montoya J, et al. Human mtDNA haplogroups associated with high or reduced spermatozoa motility. Am J Hum Genet 2000; 67: 682–96.
30 van der Ven K, Fimmers R, Engels G, van der Ven H, Krebs D. Evidence for major histocompatibility complex-mediated effects of spermatogenesis in humans. Hum Reprod 2000; 15: 189–95.
31 Holroyke AJ, McHugh P, Wu M, O’Carroll S, Benny P, et al. High incidence of single nucleotide substitutions in the mitochondrial genome is associated with poor semen parameters in men. Int J Androl 2001; 24: 175–82.
32 Krausza, Rijpstra-De Meets Y, Frydelind-Larsen L, Quintana-Murci L, McCleavey K, et al. Double-blind Y chromosome microdeletation analysis in men with known sperm parameters and reproductive hormone profiles: microdeletions are specific for spermatogenic failure. J Clin Endocrinol Metab 2001; 86: 2638–42.
33 Kuiviväli A, Georgiou I, Boubia I, Tsirka A, Giannouli CH, et al. Association of oestrogen receptor alpha polymorphisms and androgen receptor CAG trinucleotide repeats with male infertility: a study in 109 Greek infertile men. Int J Androl 2002; 25: 149–52.
34 Tsujimura A, Ota M, Katsuyama Y, Sada M, Miura H, et al. Susceptibility gene for non- obstructive azoospermia located near HLA-DR and -DQ loci in the HLA class II region. Hum Genet 2002; 110: 192–7.
35 Asatiani K, von Eckardstein A, Simonis M, Grömling J, Nieschlag E. CAG repeat length in the androgen receptor gene affects the risk of male infertility. Int J Androl 2003; 26: 255–61.
36 Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannides DG. Replication validity of genetic association studies. Nat Genet 2001; 29: 306–9.
37 Patrizio P, Liu Y, Sonek GJ, Benss MW, Tadir Y. Effect of pentoxifylline on the intrinsic swimming forces of human sperm assessed by optical tweezers. J Androl 2000; 21: 753–6.